Why carry out this study?

Current standards for identifying impairment are based on body fluid testing to detect recent cannabis use and behavioral assessments; therefore, determining cannabis impairment with accuracy and objectivity is crucial as legalization has increased use

The objective of this study was to assess the accuracy, sensitivity and specificity levels of a new electroencephalography (EEG)-based technology, the Cognalyzer®, for assessing cannabis’ psychoactive effects and characterize brainwave alterations associated with cannabis inhalation

What was learned from the study?

The accuracy of the Cognalyzer® was 83.6–85.5%, sensitivity was 85.1–88.7% and specificity was 79.0–85.1%

Combining the Cognalyzer® test with readily accepted oral fluid testing for THC improved the diagnostic performance of each test

The robustness of the Cognalyzer® test is evident in its ability to maintain high levels of accuracy in a population of participants with variable cannabis use histories, addressing a significant limitation of currently accepted methods